A replication-defective recombinant adenovirus (Ad) expressing the full length Epstein-Barr virus (EBV) major envelope glycoprotein gp340/220 was tested for its ability to protect against EBV-induced lymphoma in the cottontop tamarin. Antibody responses against Ad capsid proteins and EBV gp340/220 were observed but these antibodies did not neutralize EBV in vitro. However, all immunized animals were protected against challenge following three intramuscular doses of the recombinant Ad. These data indicate that the recombinant Ad is potentially a useful vector for vaccination.
A replication-defective recombinant adenovirus (Ad) expressing the full length Epstein-Barr virus (EBV) major envelope glycoprotein gp340/220 was tested for its ability to protect against EBV-induced lymphoma in the cottontop tamarin. Antibody responses against Ad capsid proteins and EBV gp340/220 were observed but these antibodies did not neutralize EBV in vitro. However, all immunized animals were protected against challenge following three intramuscular doses of the recombinant Ad. These data indicate that the recombinant Ad is potentially a useful vector for vaccination.
Among live virus vaccine candidates, human adenoviruses (Ad) are particularly attractive. Ad vaccines based on serotypes 4 and 7 have proved safe and efficient when administered to U.S. military recruits for over 30 years. Oral administration with enteric-coated tablets containing both lyophilized serotypes produces an asymptomatic intestinal infection inducing protection against Ad acute respiratory disease (Top et al., 1971 a, b) . Oral types 1, 2 and 5 Ad vaccines have also been evaluated and shown to be safe in volunteers during a clinical trial (Schwartz et al., 1974) . Extensive knowledge of Ad molecular biology and structure has provided the basis for its adaptation as an expression vector (Berkner, 1992) and the Ad genome (36 kbp) is large enough to accommodate 7"5kbp of exogenous DNA. Once generated, the Ad recombinants are stable with few observed rearrangements. Large virus stocks with titres ranging from l0 s to 101° p.f.u./ml can be obtained from human cells grown in tissue culture. These properties have generated considerable interest in developing recombinant Ad as potential live vaccines.
Recombinant Ad vaccine vectors have been constructed using glycoprotein genes from a variety of animal viruses (Berkner, 1992) . The first immunogenic protein expressed was the hepatitis B surface antigen (HBs Ag) (Ballay et al., 1985) . Recombinant Ad7 and Ad5 harbouring HBs Ag were found capable of partially protecting chimpanzees (Lubeck et aL, 1989; Levrero et al., 1991) . Ad vectors expressing herpes simplex virus glycoprotein gB (McDermott et al., 1989) , vesicular stomatitis virus glycoprotein (Prevec et al., 1989) , rabies virus glycoprotein (Prevec et al., 1990) or pseudorabies virus gp50 (Eloit et al., 1990) induce neutralizing antibodies and protection against a viral challenge in various animals. More recently, the first human use of an Ad vaccine vector expressing HBs Ag in a phase 1 study in volunteers has been described (Tacket et al., 1992) .
We have used a viral vector based on Ad serotype 5. In contrast to serotype 7, this serotype is non-oncogenic in rodents. Moreover, it has been entirely sequenced (Chroboczek et al., 1992) and deletion mutants in the E1 and the E3 regions have been made (Shenk & Williams, 1984) . The E1A region encodes the immediate early proteins that trans-activate all other early regions. The recombinants obtained after cloning the foreign gene into the E1 region are thus replication-defective in permissive cells and must be amplified in 293 cells, an E 1-complementing human cell line (Graham et al., 1977) . Nevertheless, we and others have already demonstrated that the expression of foreign genes in vitro is not restricted to cells complementing the El defect but, on the contrary, can be obtained at high levels in various cell lines infected with these recombinant Ad constructs. Moreover, when injected into animals, they can induce good humoral immune responses even in the absence of viral replication (Ballay et al., 1985; Alkhatib & Briedis, 1988; Eloit et al., 1990; Ragot et al., 1991 ; Levrero et al., 1991) .
The Epstein-Barr virus (EBV) is strongly associated with endemic Burkitt's lymphoma and undifferentiated nasopharyngeal carcinoma (NPC) in developing countries (Epstein & Achong, 1986) . NPC is the commonest turnout of men in Southern China, with a high incidence in South-East Asia and North Africa and up to 80 000 new cases being recorded every year (Parkin et al., 1984) . EBV DNA is also found in isolated tumour cases such as palatine tonsil and salivary gland carcinomas (Raab-Traub et al., 1991) . In the more developed countries, EBV causes infectious mononucleosis. The risk of developing this disease is 50 % where primary infection is delayed until adolescence. It is also implicated in the high number of lymphomas arising in immunosuppressed patients who are organ transplant recipients or AIDS sufferers (Thomas & Crawford, 1989) . There are also rare cases of a fatal X-linked lymphoproliferative syndrome which is the result of an ineffective cellular immune response against EBV (Grierson & Purtilo, 1987) . More recently, a growing number of Hodgkin's lymphomas have been associated with EBV as these tumours express a number of EBV latent antigens (Mfiller et al., 1989; Pallesen et al., 1991) .
Considerable evidence points to the importance of the EBV major envelope glycoprotein gp340/220 in immunity to EBV infection. Gp340/220 is expressed on the outer surface of virions and infected cells and induces virus-neutralizing antibodies (Morgan et al., 1983 (Morgan et al., , 1984 (Morgan et al., , 1989 Morgan, 1992) , T cell-mediated responses (Bejarano et al., 1990; Wallace et al., 1991) and antibodydependent cellular cytotoxicity (ADCC) (Khyatti et al., 1991) . Moreover, immunization with a purified gp340 subunit vaccine can induce protective immunity against EBV-induced lymphomas in the cottontop tamarin (Epstein et al., 1985; Morgan et al., 1988a Morgan et al., , 1989 . Previous experiments have been carried out using recombinant vaccinia virus (Morgan et al., 1988b) and varicella-zoster virus (Lowe et al., 1987) . We have constructed recombinant Ad expressing full-length gp340/220. The recombinant gp340/220 was detected by immunoprecipitation of infected cell extracts and by immunofluorescence at the surface of infected cells using monoclonal antibodies. Recombinant Ad constructs have been shown to be efficient at inducing antigp340/220 antibodies in rabbits and their sera were also found to be EBV-neutralizing in vitro (Ragot et al., 1990 (Ragot et al., , 1991 . Here we describe the testing of one of these recombinants for its ability to protect cottontop tamarins ( Saguinus oedipus oedipus) against EBV-induced lymphoma.
The construction of the recombinant Ad expressing gp340 (Ad-gp340) has been previously described (Ragot et al., 1991) . Briefly, the gp340/220 gene from nucleotides 92163 to 89207 in the B95-8 viral genomic sequence was cloned into the expression vector pMLP10, downstream of the viral cis-acting elements and under the control of the Ad2 major late promoter associated with its tripartite leader (Levrero et al., 1991) . The recombinant plasmid and the large fragment of CIaI-restricted Ad-d1324 (Shenk & Williams, 1984 genome were cotransfected into 293 cells and the recombinant Ad-gp340 was recovered after in vivo recombination (Berkner, 1992) .
The ability of recombinant adenovirus expressing gp340 to protect cottontop tamarins from EBV-induced disease was tested in six animals that were negative for antibodies to EBV gp340 as measured by ELISA (Randle & Epstein, 1984) , to EBV capsid antigen as measured by immunofluorescence (Henl~ & Henlr, 1966) and to Ad capsid proteins as measured by immunofluorescence (Kasel, 1980) . Four tamarins were immunized with Adgp340, one with the non-recombinant Ad (Ad-d1324) and one remaining as a negative control. Viral stocks were made on 293 cells that were harvested 30 h post-infection and pelleted by centrifugation. Fresh medium was added and the cells were broken by four cycles of freezing and thawing. Cell fragments were removed by centrifugafion and the virus was purified by banding twice in CsC1 density gradients, with care being taken to avoid carrying over gp340/220 from cell extracts, and extensively dialysed. The virus titre was checked by plaque assay on 293 cells before inoculation. Three intramuscular injections were given; the first was a dose of 5 × 109 p.f.u, in 1 ml of PBS and because the tamarins gave no adverse reactions the dose was increased to 101° p.f.u, and 2x 101° p.f.u, respectively for the second and third injections given on weeks 5 and 13. Blood samples were taken on the day of the first injection (pre-bleed) and then weekly. Tamarin plasma samples were assayed for antibody responses to gp340 by ELISA. The assay was carried out essentially as described by Randle & Epstein (1984) except that the microtitre plates were coated with gp340 purified from the membranes of EBV-infected cells by FPLC (David & Morgan, 1988) . Antibodies to Ad capsid antigens were measured by immunofluorescence and the Ad serotype 5 was ascertained by haemagglutination (Rosen, 1960) . All four tamarins that received recombinant Ad developed antibodies to gp340 reaching low titres ranging from 1/100 to 1/280 at 3 weeks after the second inoculation (Table 1 ). The antigp340 antibody levels were elevated by the third injection and antibody titres ranging from 1/440 to 1/1520 were measured 3 weeks later (Table 1) . Furthermore, these antibodies were confirmed to be specific for gp340 following analysis by Western blotting using membranes of EBV-infected cells as the source of gp340 (data not shown). The plasma samples did not reduce the ability of EBV to infect cord blood lymphocytes in vitro using standard techniques (De Schryver et al., 1974) and therefore the anti-gp340 antibodies appeared not to be virus-neutralizing, even in the presence of complement, as the plasma samples were not heat-inactivated and had been stored at -70 °C for only several weeks. All five tamarins inoculated with Ad, including the one animal which received the parental virus, developed antibodies to Ad capsid antigens (Table 1) .
Three weeks after the third Ad inoculation the five tamarins plus the animal which had not been immunized were challenged with a 100 % tumorigenic dose of EBV from a pre-tested batch of virus prepared from the B95-8 cell line, administered intramuscularly and intraperitoneally, as previously described (Cleary et al., 1985) . Prior to the present experiment, two EBV seronegative tamarins were inoculated with the same batch of virus used for this challenge and both developed extensive EBV-induced disease involving both the peripheral and abdominal lymph nodes as previously reported (Cleary et al., 1985) . Following the present EBV challenge, all six tamarins were regularly monitored by external palpation and measurements were taken of lymph node tumours. The results are shown in Fig. 1 which illustrates the tumour load in each tamarin following EBV challenge. The growth of EBV-induced tumours has previously been expressed in terms of increases in the sum of the radii of the lymph nodes (Morgan et al., 1989) . However, this does not account for the spherical shape of the turnouts and we consider that tumour development is better expressed in terms of the increase in volume, as has previously been used for the development of mammary carcinomas in mice infected with mammary tumour virus (Attia & Weiss, 1966) . The tamarin (R155) which received parental Ad developed rapidly progressive EBVinduced disease following EBV challenge in line with that observed in the two tamarins used to pre-test the virus batch. The animal was humanely destroyed owing to extensive disease 25 days after injection of EBV. There was involvement of both peripheral and abdominal lymph nodes. The spleen was found to be very enlarged and multiple mesenteric lymph nodes (more than 20) were removed from the abdomen post mortem. The unimmunized negative control tamarin (B159) also developed extensive EBV-induced disease; the tumour burden increased rapidly up to around 28 days after EBV injection to give a profile similar to that of tamarin R155 (Fig. 1) , thereafter the tumour burden decreased. A proportion of tamarins have previously been reported to recover in this manner following tumour development (Cleary et al., 1985) . In contrast to these animals, the four tamarins which were immunized with recombinant Ad expressing gp340 were clearly protected and did not develop any disease following injection of EBV; only some minor lymph node enlargements were detected (Fig. 1) . This involved mainly the peripheral lymph nodes and in particular the inguinal lymph nodes. Any Short communication abdominal involvement was transitory and typically nodes of around 14 mm ~ volume only were detected, in contrast to the two unprotected control tamarins where abdominal masses of over 1000 mm 3 volume were present. Similar transient lymph node enlargement has previously been reported in tamarins protected from extensive EBV-induced disease by various immunization schedules. Biopsies taken in those studies did not show the characteristics of tumour tissue (Cleary et al., 1985; Morgan et al., 1988a) .
We report here the first complete protection obtained in a primate model with a replication-defective Ad. Eloit et al. (1990) have demonstrated a partial protection of rabbits and mice (one-third of the animals were protected) against pseudorabies virus after immunization with recombinant Ad expressing pseudorabies virus gp50. A proportion of chimpanzees could be protected against hepatitis B virus challenge after vaccination with recombinant Ad expressing HBs Ag (Levrero et al., 1991) . In this experiment three higher intramuscular doses (5 x 109 to 2 x 10 l° p.f.u.) were used as compared to the three intravenous doses of 109 p.f.u, in the chimpanzee vaccination trial (Levrero et al., 1991) and no side-effects have been observed. We have not yet investigated whether a lower dose could also protect animals from disease, but our main aim in future work will be to reduce the virus dose and the number of vaccinations necessary to obtain similar protection. Here intramuscular injection of the recombinant virus was used, but the possibility of obtaining an effective immune response by intranasal introduction has been shown in the rabbit (Ragot et al., 1991) . Immunization using either a nasal route or enteric-coated capsules via the oral route is promising for anti-EBV vaccine development and this is currently being tested in cottontop tamarin protection experiments.
The mechanism of protection given by various gp340-based vaccines in the cottontop tamarin is obviously of great interest and the subject of ongoing studies. It is possible that different mechanisms prevail depending on the type of vaccine given. For instance a subunit vaccine which would present an exogenous antigen to the immune system could well protect by a mechanism different to that of a live recombinant virus vaccine which would present endogenous antigen to the immune system. In a tamarin vaccination experiment using the WR strain vaccinia virus gp340 recombinant, antibodies against vaccinia virus proteins were detected in the sera from vaccinated animals but no antibodies were seen against the gp340 glycoprotein, whether or not the animal in question was protected against EBV lymphoma (Morgan et al., 1988b) . It might be deduced that the animals were protected by a cell-mediated immune response. In contrast, we have observed a good antibody response against gp340 in the experiment reported here, comparable to that obtained in rabbits with the same recombinant Ad (Ragot et al., 1991) and titres similar to those obtained in tamarins with a subunit vaccine (Epstein et al., 1985) . Nevertheless, as these sera are not EBV-neutralizing in vitro, it would seem that the cellular component of the response is of major importance for the protection of the tamarins. Helper T cell and cytotoxic T cell activities are currently being investigated following immunization of tamarins with recombinant Ad.
In previous work there has been an absence of correlation between neutralizing antibody and protection . Furthermore, it is clear that a vaccine need not elicit neutralizing antibodies for protection to be obtained as shown both in the present study and in earlier work (Morgan et al., 1988b) . Sera used in the present experiment in neutralization assays should contain active complement since they are stored at -70 °C and are not heat-inactivated. This should ensure that any neutralization activity is detected whether it is complement-dependent or not. Other antibodymediated mechanisms, such as ADCC (Khyatti et al., 1991) , may be important but none have yet been detected (unpublished data). In vitro studies have shown that gp340-primed T cells can inhibit EBV transformation (Bejarano et al., 1990) . The possibility that a similar cellmediated mechanism may occur in vivo in tamarins is being studied. Furthermore, only a very small amount of antigen is required on the cell surface for a cell to become a target for cytotoxic T lymphocytes. It is a further possibility that in the early stage of infection tamarin B cells may express such low levels as to be undetectable by conventional means and be lysed by a cell-mediated mechanism. The mechanism of protection against tumour induction could be by the killing of tumour cells by these means or by the killing of infected cells shortly after viral challenge but before tumour cells are generated. Alternatively, tumour cells may arise following viral replication after delivery of the challenge dose and it is at this point that the immune system of the vaccinated animal may act.
The use of recombinant live viruses as vaccine vectors has many advantages over subunit vaccines. Effective T cell antigen presentation occurs, generating a broadranging response among other T cell components along with memory induction, the absence of a need for adjuvants and low production costs. But the main disadvantage is the possibility of horizontal transmission between humans or between humans and other animal species, due to the wide host range of some of these live viruses. In the case of vaccinia and polio viruses, transmission to immunocompromised individuals through contact with vaccinated individuals has had severe consequences. The human adenoviruses have a relatively narrow host range for replication (i.e. mainly in humans). Infection by vaccinated individuals of close contacts has exceptionally been reported during the trials performed on recruits to the U.S. armed forces with wild-type Ad serotypes 4 and 7 (Top et al., 1971a) . However type 4 attenuated vaccine strains given to small numbers of children during a clinical trial resulted in spread of the infection to household contacts (MOller et al., 1969) . In the same manner, cross-infection of the Ad type 4 vaccine in married couples has been well documented (Stanley & Jackson, 1969) . As a replicationdefective recombinant is used here, this should no longer be a problem.
Vaccinia and varicella-zoster virus live vector vaccines can provoke occasional complications, for example postvaccinal encephalitis for vaccinia virus (Murphy, 1989) . Attempts have been made to attenuate this virus (Williamson et al., 1990; Lee et al., 1992) , but it has not been possible, until recently , to reduce the virulence of vaccinia virus while maintaining its immunogenicity at an acceptably high level. No protection was obtained using a vaccinia virus gp340 recombinant (Morgan et al., 1988b) when the recombinant was derived from an attenuated vaccine strain (Wyeth). In contrast, a recombinant vaccine based on a laboratory strain (WR) could protect tamarins but caused extensive lesions (Morgan et al., 1988 b) . Ad type 5 infections are generally subclinical and can be responsible for mild disease in immunocompetent individuals due to the cytopathic effects of viral replication in infected cells. Complications have not been recorded in the large number of people who have been vaccinated by the enteric-coated wild-type Ad vaccine. In this respect a replication-defective adenovirus should increase the safety factor still further.
Another possible problem is that virulent revertants may arise from attenuated strains and cause disease, e.g. immunization with attenuated poliovirus can occasionally lead to vaccine-related poliomyelitis. This kind of event is unlikely with the recombinant Ad as the E1 region is completely deleted and replaced by the expression cassette of the gp340/220 gene. In addition, because of size limitations in Ad packaging, where only 105 % of the normal genome size can be packaged, it should not be possible to obtain a recombinant virus carrying both the E1 and gp340/220 genes by recombination with wild-type Ad. However, cells already infected with the replication-defective recombinant could be complemented for by infection with a wild-type Ad which could provide the E 1 region's functions. Packaging sequences of the recombinant virus are being modified to counterselect it in the presence of a wild-type Ad infection.
A third problem is to verify whether a primary immunization with the vaccine-based vector proteins impairs subsequent immune responses against the foreign antigenic protein produced from this vector. This appears to be the case with vaccinia virus in mice (Rooney et al., 1988) and in humans (Cooney et al., 1991) . Another advantage of the replication-defective Ad in humans may be reduction of immune responses against the Ad capsid proteins, allowing multiple vaccinations without affecting the quality of the immunization against the foreign antigen(s) whose genes are the only ones expressed.
Productive replication of the viral vector is apparently not essential for the induction of protective immunity as has also been observed for the poxviridae . The expression of an exogenous gene coding for foreign antigen without any viral protein synthesis, without virus-induced host cell shutoff and presentation of the immunogen at the plasma membrane of the infected cells appears to compensate for the absence of replication. A replication-defective Ad vector will greatly increase the safety factor required for its possible use in human vaccination. 
